Meng Qinghong, Zheng Yan, Chen Xiaobo, Mu Jiawei, Li Changlin, Gao Yiwen, Liu Wei, Wang Yuliang
Department of Clinical Laboratory Medicine, The Eco-city Hospital of Tianjin Fifth Central Hospital, Tianjin, China.
Clinical Laboratory, Wanxin Street Community Healthcare Center, Tianjin, China.
Int J Med Sci. 2025 Jul 28;22(14):3692-3708. doi: 10.7150/ijms.115650. eCollection 2025.
Aging has become one of the most significant challenges and burdens on public health and healthcare systems worldwide. However, it is possible to slow down the aging process through various interventions. Mesenchymal stromal/stem cells (MSCs) have emerged as one of the most promising therapeutic agents for combating aging and treating various age-related chronic medical conditions. This is primarily due to their well-known cellular plasticity and potent multipotency, which enable them to promote tissue repair and regeneration, as well as address inflammatory conditions. Remarkably, the high quality and functional activity of MSCs are negatively affected by cellular senescence, particularly in both healthy-aging MSCs and replicative senescent MSCs. This is a critical issue when considering the provision of "personalized" or "universal" clinical-grade products. Therefore, this review aims to summarize the biological properties, immunomodulatory dysfunction, and underlying mechanisms of senescent MSCs. Additionally, it discusses the current promising techniques published for rejuvenating senescent MSCs and optimizing their therapeutic potential.
衰老已成为全球公共卫生和医疗保健系统面临的最重大挑战和负担之一。然而,通过各种干预措施减缓衰老过程是有可能的。间充质基质/干细胞(MSCs)已成为对抗衰老和治疗各种与年龄相关的慢性疾病最有前景的治疗剂之一。这主要是由于它们众所周知的细胞可塑性和强大的多能性,使其能够促进组织修复和再生,并应对炎症状况。值得注意的是,MSCs的高质量和功能活性受到细胞衰老的负面影响,特别是在健康衰老的MSCs和复制性衰老的MSCs中。在考虑提供“个性化”或“通用”临床级产品时,这是一个关键问题。因此,本综述旨在总结衰老MSCs的生物学特性、免疫调节功能障碍及其潜在机制。此外,还讨论了目前为使衰老MSCs恢复活力并优化其治疗潜力而发表的有前景的技术。